Prelude Therapeutics (PRLD) Net Margin (2024 - 2026)

Prelude Therapeutics (PRLD) posted Net Margin of 752.05% for Q1 2026, down 134.57% sequentially from 320.6% in Q4 2025.

Prelude Therapeutics (PRLD) Net Margin (2024 - 2026) Analysis & Trends

Prelude Therapeutics has reported Net Margin for 3 years, with the latest figure at 752.05% in Q1 2026.

Quarterly Net Margin changed N/A year-over-year to 752.05% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 891.23% (changed N/A YoY) and the FY2025 annual result came in at 2606.84%, up 199825.0% from the prior year.
Net Margin fell to 752.05% in Q1 2026 per PRLD's latest filing, from 320.6% in the prior quarter.
Over five years, Net Margin peaked at 320.6% in Q4 2025 and troughed at 2549.4% in Q3 2024.
A 3-year average of 1025.52% and a median of 752.05% in 2026 frame the typical range for Net Margin.
The widest YoY moves for Net Margin: up 190294 bps in 2025, down 53847 bps in 2025.
Over 3 years, Net Margin stood at 859.08% in 2024, then surged by 63 bps to 320.6% in 2025, then tumbled by 135 bps to 752.05% in 2026.
According to Business Quant data, Net Margin over the past three periods registered 752.05%, 320.6%, and 646.46% for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Margin (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	32.99%
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	30.23%
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	30.33%
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	13.90%
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	30.98%
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	12.09%
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	12.74%
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-3.12%
10	Prelude Therapeutics	442.91 Mn	162.28 Mn	-	-924.05%

Download Data